Melbourne-based Rhythm Biosciences announced the delivery of the first Alpha version of its multiplex antibody detection kits, a key advancement in its next-generation colorectal cancer diagnostics.
The kits, produced by Quansys Biosciences in the USA, serve as functional prototypes for the final product designed to detect colorectal cancer using patient blood samples.
The development marks a significant step for the company, enabling further in-house assay testing before final design and clinical validation.
The multiplex assay integrates five separate antibody-based assays into a single reaction, aimed at improving reliability and reducing turnaround time, assay throughput, and overall costs.
"The initial Alpha test results have exceeded my initial expectations," said David Atkins, CEO of Rhythm.
Kyle Berg, research and development manager at Quansys, praised the collaboration, stating, "The assay design has been complex, and reaching this point with these results highlights the expertise and dedication of the Quansys R&D team, the critical antibody selection work by Rhythm, and the strength of our collaborative efforts along the way."
To support the commercial launch, Rhythm is collecting customer insights and is focused on optimising colonoscopy triage by utilising its assay to prioritise individuals scheduled for the procedure.
The company also aims to explore intermediate clinical applications that represent steps towards a general colorectal cancer screening assay.
Additionally, Rhythm Biosciences is engaging experienced consultants to revise its regulatory strategy for an appropriate market entry path.
Rhythm Biosciences is a medical diagnostics company engaged in delivering simple, affordable blood tests for accurate and early detection of cancers. It is focused on improving patient outcomes through detection at the earliest possible stage.
At the time of reporting, Rhythm Biosciences’ share price was $0.067.